A patient-centred framework for pharmacist-led atrial fibrillation better care: the pharm-abc study / Hanis Hanum Zulkifly

Atrial fibrillation (AF) is a common cardiac arrhythmia that affects approximately 33 million people worldwide. AF is associated with significant morbidity and mortality, including a fivefold increased risk of stroke, heart failure, and other cardiovascular complications[1]. They also face significantly higher mortality rates (25% vs. 8.7%) and greater functional disability from stroke complications compared to those without AF[2]. Despite advances in pharmacological therapy, the management of AF remains challenging due to its complex nature and the need for individualized care. Despite the availability of evidence-based guidelines for the management of AF, many patients receive suboptimal care, leading to poor outcomes.